A transcriptomic, metabolic and phenotypic study of the anti-fibrotic effects of PGE2 in IPF lung fibroblasts and macrophages
K. Wiqvist (Mölndal, Sweden), M. Ingelsten (Mölndal, Sweden), Z. Jevnikar (Mölndal, Sweden), O. Bilkei-Gorzo (Gothenburg, Sweden), T. Ottosson (Mölndal, Sweden), T. Markou (London, United Kingdom), J. Lindgren (Mölndal, Sweden), T. Maher (London, United Kingdom), P. Molyneaux (London, United Kingdom), M. Göransson (Mölndal, Sweden)
Source: International Congress 2022 – Emerging therapeutic targets, biomarkers and mechanisms of chronic lung disease
 
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
K. Wiqvist (Mölndal, Sweden), M. Ingelsten (Mölndal, Sweden), Z. Jevnikar (Mölndal, Sweden), O. Bilkei-Gorzo (Gothenburg, Sweden), T. Ottosson (Mölndal, Sweden), T. Markou (London, United Kingdom), J. Lindgren (Mölndal, Sweden), T. Maher (London, United Kingdom), P. Molyneaux (London, United Kingdom), M. Göransson (Mölndal, Sweden). A transcriptomic, metabolic and phenotypic study of the anti-fibrotic effects of PGE2 in IPF lung fibroblasts and macrophages. 3567
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|